Fortress Biotech, Inc.

Fortress Biotech, Inc. Earnings Recaps

FBIO Health Care 1 recap
Q3 2025 Nov 13, 2025

Journey Medical delivered robust performance in Q3 2025, achieving 21% year-over-year revenue growth, driven primarily by the strong uptake of its new oral treatment, EMROSI.

Key takeaways
  • EMROSI contributed $4.9 million, showing a 75% revenue increase compared to Q2, with total prescriptions growing 146%.
  • Despite a 16% year-over-year decline in revenue for legacy products due to Accutane generic competition, overall product revenues grew by more than 16% year-over-year.
  • Operating expenses rose only 9%, highlighting effective expense management linked to EMROSI's launch and potential for sustainable EBITDA positivity in Q4.
  • Over 2,700 unique prescribers have adopted EMROSI, a 50% increase since the last earnings call, indicating strong market acceptance and growth potential.
  • The company has secured access for EMROSI across over 100 million of the 187 million commercial lives, with further GPO contracting expected.
Full recap